基药目录管理办法时隔11年首次修订，突出药品临床价值

Core Viewpoint - The new management measures for the National Essential Medicines List emphasize the selection of drugs based on their clinical value and establish a rigid adjustment cycle of no more than three years for the list [1][2][3] Group 1: Essential Medicines List Management - The revised management measures state that the essential medicines should meet basic medical needs, be suitable for current national conditions, and ensure supply and affordability [2] - The previous version of the management measures had not been updated since 2018, with the current list containing 685 drug varieties [2] - The new measures highlight the importance of timely adjustments to the essential medicines list, with a focus on dynamic management and regular evaluations [2][3] Group 2: Clinical Value and Drug Selection - The new management measures stress the importance of clinical value in drug selection, aiming to include more innovative drugs that meet clinical needs [3][5] - The selection process for the essential medicines list does not accept applications from companies; instead, it is determined by a coordination mechanism involving 11 departments [3][5] Group 3: Coordination with Other Policies - The revised measures aim to improve coordination with other healthcare policies, including medical insurance and centralized procurement [6][8] - The management measures have removed the requirement for all grassroots medical institutions to exclusively use essential medicines, allowing for more flexibility in drug selection [7] - Future adjustments to the essential medicines list will consider various factors, including public health needs, disease spectrum changes, and drug safety monitoring [9]